PDCD1 and melanoma: To date, the phases I and II clinical trials (~130 patients in total) determined the optimal dose and showed that the combinatorial treatment of PD-1/PD-L1 blockade with IFNα/β is safe and efficient for particularly melanoma and to some extent for renal carcinoma patients (Table 2).